Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.77 |
| ▸ | TP53 | P04637 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.77 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.63 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.63 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.63 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.63 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.63 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.63 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.63 |
| ▸ | ACHE | P22303 | 4/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | TYMP | P19971 | 1/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.44 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.44 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3163131 | 1.00 | LMNA (0.77) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL13264312 | 1.00 | LMNA (0.77) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL6887845 | 1.00 | LMNA (0.77) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL14075781 | 1.00 | LMNA (0.77) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL14030780 | 1.00 | LMNA (0.77) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL10001661 | 1.00 | LMNA (0.77) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL14088746 | 1.00 | LMNA (0.77) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL6363723 | 0.95 | LMNA (0.70) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL20705942 | 0.93 | LMNA (0.67) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL471152 | 0.92 | LMNA (0.66) | LMNAALDH1A1TP53MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-57171998-A | — | — | None | — | — | JP | disclosed |
| US-20220152077-A1 | ADENOSINE RECEPTOR AGONISTS | THE UNIVERSITY OF WARWICK (GB) | 2022-05-19 | — | — | US | disclosed |
| US-20150376219-A1 | Selective Preparations of Purine Nucleosides and Nucleotides: Reagents and Methods | ZHONG MINGHONG (US) | 2015-12-31 | — | — | US | disclosed |
| US-20120202287-A1 | Stem Cell Culture Methods | ITI SCOTLAND LIMITED (GB) | 2012-08-09 | — | — | US | disclosed |
| US-20090324708-A1 | COMPOUND HAVING INHIBITORY ACTIVITY ON A RHO-GTPASE CELL PROTEIN, A PROCESS FOR OBTAINING THE SAME, PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF AND A METHOD FOR THE TREATMENT OF RHO-GTPASE CELL PROTEIN-MEDIATED CONDITION | UNIVERSIDAD NACIONAL DE QUILMES (AR) | 2009-12-31 | — | — | US | disclosed |
| US-7579162-B2 | Method of detection in homogeneous phase, especially of progesterone in mammals' milk, and corresponding kit | CEVA SANTE ANIMALE (FR) | 2009-08-25 | — | — | US | disclosed |
| US-20070042449-A1 | Method of detection in homogeneous phase, especially of progesterone in mammals' milk, and corresponding kit | CEVA SANTE ANIMALE (FR) | 2007-02-22 | — | — | US | disclosed |
| US-7026478-B2 | Iron catalyzed cross coupling reactions of aromatic compounds | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2006-04-11 | — | — | US | disclosed |
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | DEVOS RENE (GB) | 2004-06-10 | — | — | US | disclosed |
| US-20030220498-A1 | Iron catalyzed cross coupling reactions of aromatic compounds | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2003-11-27 | — | — | US | disclosed |
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | F. HOFFMAN-LA ROCHE, A SWISS COMPANY (CH) | 2003-01-09 | — | — | US | disclosed |
| WO-2002018404-A2 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-07 | — | — | WO | disclosed |
| WO-2000075158-A2 | NOVEL 6-PHENYLPURINE 9-β-D-RIBONUCLEOSIDES WITH ANTINEOPLASTIC ACTIVITY, THEIR USE FOR PREPARING PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL PREPARATIONS CONTAINING SUCH COMPOUNDS | ÚSTAV ORGANICKÉ CHEMIE A BIOCHEMIE AKADEMIE VĚD ČESKÉ REPUBLIKY (CZ) | 2000-12-14 | — | — | WO | disclosed |
| EP-0458519-A2 | Synthesis of nucleotide and nucleoside derivatives | EFAMOL HOLDINGS PLC (GB) | 1991-11-27 | — | — | EP | disclosed |
| US-4992535-A | Cardiovascular disorders; side effect reduction | G. D. SEARLE & CO. (US) | 1991-02-12 | — | — | US | disclosed |
| EP-0368071-A1 | Methods of making novel R and S diastereomers of N6-[(2-hydroxypropyl)aryl]adenosines | G.D. Searle & Co. (US) | 1990-05-16 | — | — | EP | disclosed |
| EP-0180614-B1 | N-6 SUBSTITUTED ADENOSINE DERIVATIVES AS CARDIAC VASODILATORS | Whitby Research Incorporated (US) | 1990-03-07 | — | — | EP | disclosed |
| US-4464361-A | Adenosine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-08-07 | — | — | US | disclosed |
| JP-S57171998-A | ADENOSINE DERIVATIVE AND ITS SALT, PREPARATION THEREOF AND MEDICINAL COMPOSITION CONTAINING THE SAME | FUJISAWA PHARMACEUT CO LTD | 1982-10-22 | — | — | JP | disclosed |
| EP-0062921-A1 | Adenosine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1982-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | PNP, HAVCR2, NUDT14 | LMNA 4330/4885ALDH1A1 596/4885TP53 3695/4885 |
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | PNP, HAVCR2, NUDT14 | LMNA 4330/4885ALDH1A1 596/4885TP53 3695/4885 |
| US-20120202287-A1 | Stem Cell Culture Methods | KIT, SOX18, MCL1 | LMNA 2410/4885ALDH1A1 20/4885TP53 1116/4885 |
| US-20030220498-A1 | Iron catalyzed cross coupling reactions of aromatic compounds | ARRB1, RBX1, CYP4X1 | LMNA 3128/4885ALDH1A1 285/4885TP53 3018/4885 |
| US-20090324708-A1 | COMPOUND HAVING INHIBITORY ACTIVITY ON A RHO-GTPASE CELL PROTEIN, A PROCESS FOR OBTAINING THE SAME, PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF AND A METHOD FOR THE TREATMENT OF RHO-GTPASE CELL PROTEIN-MEDIATED CONDITION | RHOA, ARHGDIA, ARHGDIB | LMNA 4307/4885ALDH1A1 4493/4885TP53 1708/4885 |
| US-20220152077-A1 | ADENOSINE RECEPTOR AGONISTS | ADORA1, ADORA2A, ADORA3 | LMNA 2249/4885ALDH1A1 281/4885TP53 4853/4885 |
| US-20150376219-A1 | Selective Preparations of Purine Nucleosides and Nucleotides: Reagents and Methods | PNP, ATIC, NT5C3B | LMNA 1004/4885ALDH1A1 3802/4885TP53 4344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.